View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Re...

UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(...

 PRESS RELEASE

AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results

AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(8%)Gross ...

Moody's Ratings assigns Baa1 rating to Amgen's notes; stable outlook

Moody's Ratings (Moody's) assigned a Baa1 rating to the new senior unsecured notes offering of Amgen Inc. ("Amgen"). There are no changes to Amgen's existing ratings including the Baa1 senior unsecured notes rating, (P)Baa1 senior unsecured shelf rating, (P)Baa1 senior unsecured medium term note pro...

Curtis Yeung ... (+2)
  • Curtis Yeung
  • Greater China Research Team

Greater China Daily: Monday, February 16, 2026

Top Stories Economics | Money Supply M0 growth was weaker in Jan 26 due to Chinese New Year effects, while M2 growth rose to 9.0% yoy, the highest since 2023. New bank loans surged to Rmb4.71t and new TSF rose to Rmb7.22t, both above consensus forecasts. However, outstanding bank loan growth fell to a record-low 6.1% yoy, highlighting fragile underlying credit demand despite strong front-loaded lending. Sector Update | Healthcare The HSHCI rose 1.8%, outperforming the HSI, which declined by 3.8...

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Merck & Co Inc: 1 director

A director at Merck & Co Inc sold 10,000 shares at 121.456USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

 PRESS RELEASE

Biogen Announces Board Chair Transition

Biogen Announces Board Chair Transition Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 9, 2026. Dr. Freire will succeed Caroline Dorsa who has decided to retire from the Biogen Board of Directors a...

AbbVie Inc.: Update to credit analysis following upgrade to A2

Our credit view of this issuer reflects its large global scale and strong competitive positions, weighed against some concentration in highly competitive products.

Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Moody's Ratings upgrades AbbVie to A2; outlook is stable

Moody's Ratings (Moody's) upgraded the ratings of AbbVie Inc. ("AbbVie") including the long-term issuer rating to A2 from A3, senior unsecured notes to A2 from A3, and the senior unsecured commercial paper rating to Prime-1 from Prime-2. At the same time, we revised AbbVie's outlook to stable from p...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch